Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium

Cancer Science

Volumn 103, Issue 7, 2012, Pages 1334-1341

  Pils, Dietmar ^a   Hager, Gudrun ^a   Tong, Dan ^a   Aust, Stefanie ^a   Heinze, Georg ^a   Kohl, Maria ^b   Schuster, Eva ^a   Wolf, Andrea ^a   Sehouli, Jalid ^c   Braicu, Ioana ^c   Vergote, Ignace ^d   Cadron, Isabelle ^d   Mahner, Sven ^e   Hofstetter, Gerda ^f   Speiser, Paul ^a   Zeillinger, Robert ^a,b  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATIONAL STUDY; FEMALE; FOCAL ADHESION; GENE EXPRESSION PROFILING; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; MICROARRAY ANALYSIS; MOLECULAR TYPING; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; UNIVARIATE ANALYSIS; VALIDATION STUDY;

ADULT; EUROPEAN UNION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 84863333944     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02306.x     Document Type: Article

References (28)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
2. Joyce T, Cantarella D, Isella C, Medico E, Pintzas A. A molecular signature for epithelial to mesenchymal transition in a human colon cancer cell system is revealed by large-scale microarray analysis. Clin Exp Metastasis 2009; 26: 569-87.
3. Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest 2005; 115: 1503-21.
4. Miecznikowski JC, Wang D, Liu S, Sucheston L, Gold D. Comparative survival analysis of breast cancer microarray studies identifies important prognostic genetic pathways. BMC Cancer 2010; 10: 573.
5. Weigelt B, Mackay A, A'Hern R et al. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol 2010; 11: 339-49.
6. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62: 10-29.
7. Gilks CB. Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. Int J Gynecol Pathol 2004; 23: 200-5.
8. Kalloger SE, Kobel M, Leung S et al. Calculator for ovarian carcinoma subtype prediction. Mod Pathol 2010; 24: 512-21.
9. De Cecco L, Marchionni L, Gariboldi M et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004; 23: 8171-83.
10. Tothill RW, Tinker AV, George J et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-208.
11. Yoshihara K, Tajima A, Komata D et al. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis. Cancer Sci 2009; 100: 1421-8.
12. Rustin GJ, Nelstrop AE, Bentzen SM, Bond SJ, McClean P. Selection of active drugs for ovarian cancer based on CA-125 and standard response rates in phase II trials. J Clin Oncol 2000; 18: 1733-9.
13. Rustin GJ, Vergote I, Eisenhauer E et al. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer 2011; 21: 419-23.
14. Saeed AI, Bhagabati NK, Braisted JC et al. TM4 microarray software suite. Methods Enzymol 2006; 411: 134-93.
15. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 1979; 6: 65-70.
16. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
18. Heinze G, Schemper M. Comparing the importance of prognostic factors in Cox and logistic regression using SAS. Comput Methods Programs Biomed 2003; 71: 155-63.
19. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
20. Clark TG, Stewart ME, Altman DG, Gabra H, Smyth JF. A prognostic model for ovarian cancer. Br J Cancer 2001; 85: 944-52.
21. Winter WE III, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-7.
22. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011; 43: 420-32.
23. Chi DS, Liao JB, Leon LF et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001; 82: 532-7.
24. Elattar A, Bryant A, Winter-Roach BA, Hatem M, Naik R. Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 2011; 10: CD007565.
25. Chon HS, Lancaster JM. Microarray-based gene expression studies in ovarian cancer. Cancer Control 2011; 18: 8-15.
26. Halder J, Lin YG, Merritt WM et al. Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 2007; 67: 10976-83.
27. Fan DM, Shi HR. Pilot study: alteration of deleted in liver cancer1 and phosphorylated focal adhesion kinase y397 cytoplasmic expression and the prognostic value in advanced epithelial ovarian carcinoma. Int J Mol Sci 2011; 12: 8489-501.
28. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-15.